Breast cancer chemoprevention

Expert Review of Anticancer Therapy

Volumn 12, Issue 2, 2012, Pages 223-228

  Gabriel, Emmanuel M ^a   Jatoi, Ismail ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

breast cancer; chemoprevention; exemestane; raloxifene; tamoxifen

Indexed keywords

EXEMESTANE; PLACEBO; RALOXIFENE; TAMOXIFEN;

ARTHRITIS; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CATARACT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; FATIGUE; HIGH RISK POPULATION; HOT FLUSH; HUMAN; INSOMNIA; LUNG EMBOLISM; NAUSEA; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UTERUS CANCER; VAGINA DISCHARGE; VASOMOTOR DISORDER;

ANDROSTADIENES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOPREVENTION; FEMALE; HUMANS; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN;

EID: 84856939897     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.206     Document Type: Review

References (25)

1. Wickerham DL. Breast cancer chemoprevention: Progress and controversy. Surg. Oncol. Clin. N. Am. 19(3), 463-473 (2010).
2. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361, 296-300 (2003). (Pubitemid 36126189)
3. Cuzick J, DeCensi A, Arun B et al. Preventive therapy for breast cancer: A consensus statement. Lancet Oncol. 12(5), 496-503 (2011).
4. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 90, 1371-1378 (1998). . Shows the benefit of tamoxifen in the prevention of breast cancer in both pre- and post-menopausal women.
5. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352, 98-101 (1998). (Pubitemid 28321321)
6. Veronesi U, Maisonneuve P, Rotmensz N et al. Italian randomized trial among women with hysterectomy: Tamoxifen and hormone-dependent breast cancer in high-risk women. J. Natl Cancer Inst. 95, 160-165 (2003). (Pubitemid 36193265)
7. Powles TJ, Ashley S, Tidy A et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J. Natl Cancer Inst. 99(4), 283-290 (2007). (Pubitemid 47073491)
8. Veronesi U, Maisonneuve P, Rotmensz N et al. Tamoxifen for the prevention of breast cancer: Late results of the Italian Randomized Tamoxifen Prevention trial among women with hysterectomy. J. Clin. Oncol. 29(17), 2327-2333 (2011).
9. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 97, 1652-1662 (2005). (Pubitemid 41672231)
10. Cuzick J, Forbes JF, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 360, 817-824 (2002). (Pubitemid 35257944)
11. Cuzick J, Forbes JF, Sestak I et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month month follow-up of the randomized IBIS-I trial. J. Natl Cancer Inst. 99, 272-282 (2007). (Pubitemid 47073490)
12. Martino S, Cauley JA, Barrett-Connor E et al. Continuing Outcomes Relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl Cancer Inst. 96, 1751-1761 (2004). (Pubitemid 39654569)
13. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281, 2189-2197 (1999). (Pubitemid 29275701)
14. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295, 2727-2741 (2006). . Shows the benefit of raloxifene in the prevention of breast cancer in postmenopausal women compared with tamoxifen.
15. Vogel VG, Costantino JP, Wickerham DL et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: Preventing breast cancer. Cancer Prev. Res. (Phila.) 3(6), 696-706 (2010).
16. Goss PE, Ingle JN, Alés-Martínez JE et al. Exemestane for breast cancer prevention in postmenopausal women. N. Engl. J. Med. 364, 2381-2390 (2011). . Shows the benefit of exemestane in the prevention of breast cancer in postmenopausal women.
17. Thürlimann B, Keshaviah A, Coates AS et al.; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005). (Pubitemid 43016814)
18. Visvanathan K, Chlebowski RT, Hurley P et al. American Society of Clinical Oncology Clinical Practice Guideline Update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J. Clin. Oncol. 27, 3235-3258 (2009). . Comprehensive review of the clinical guidelines for breast cancer chemoprevention based on results from randomized controlled trials.
19. Davidson NE, Kensler TW. 'MAPping' the course of chemoprevention in breast cancer. N. Engl. J. Med. 364(25), 2463-2464 (2011).
20. King MC, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP P-1) breast cancer prevention trial. JAMA 286, 2251-2256 (2001). (Pubitemid 33063147)
21. Narod SA, Brunet JS, Ghadirian P et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356(9245), 1876-1881 (2000).
22. Pujol P, Lasset C, Berthet P et al.; on behalf the French Federation of Cancer Centres (FNCLCC). Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: The LIBER trial. Fam. Cancer doi:10.1007/s10689-011-9484-4 (2011) (Epub ahead of print).
23. Day R; National Surgical Adjuvant Breast and Bowel Project P-1 study (NSABP-1). Quality of life and tamoxifen in a breast cancer prevention trial: A summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann. NY Acad. Sci. 949, 143-150 (2001).
24. Ganz PA, Land SR. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer. Menopause 15(4 Suppl. 4), 797-803 (2008).
25. Freedman AN, Yu B, Gail MH et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J. Natl Cancer Inst. 99(9), 727-737 (2007).